Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2014 - 2023)

Myriad Genetics (MYGN) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $2.7 million in Q3 2023.

• Non-Current Deferred Tax Liability for Q3 2023 came in at $2.7 million, down 74.29% year-over-year; the trailing twelve-month figure through Sep 2023 was $2.7 million (down 74.29% YoY), and the FY2022 annual result was $3.5 million, down 97.28% from the prior year.
• Non-Current Deferred Tax Liability fell to $2.7 million in Q3 2023 per MYGN's latest filing, from $3.7 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $174.3 million in Q4 2020 and troughed at $2.7 million in Q3 2023.
• A 5-year average of $52.7 million and a median of $58.2 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2020 and 2022: Non-Current Deferred Tax Liability surged 130.86% in 2020, then sank 97.28% in 2022.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $75.5 million in 2019, then surged by 130.86% to $174.3 million in 2020, then dropped by 26.22% to $128.6 million in 2021, then slumped by 97.28% to $3.5 million in 2022, then decreased by 22.86% to $2.7 million in 2023.
• Business Quant data shows MYGN's Non-Current Deferred Tax Liability at $2.7 million in Q3 2023, $3.7 million in Q2 2023, and $4.1 million in Q1 2023.